Date: 2016-01-20
Type of information: Licensing agreement
Compound: CAP®GT technology for the production of lentiviral and adenoviral vectors
Company: CEVEC Pharmaceuticals (Germany) Beckman Research Institute of City of Hope (USA - CA)
Therapeutic area: Technology - Services
Type agreement: licensing collaboration
Action mechanism: gene therapy
Disease:
Details: * On January 20, 2016, CEVEC Pharmaceuticals announced a collaboration agreement with Beckman Research Institute of City of Hope on CEVEC's proprietary CAP®GT technology. Under the terms of the agreement, CEVEC will grant Beckman Research Institute a non-exclusive license for the production of lentiviral and adenoviral vectors using CEVEC's CAP®GT technology. Beckman will offer CAP®GT-derived lentiviral and adenoviral therapeutic vectors to support phase I and II clinical trials of clinical investigators, while CEVEC will provide the relevant licenses.
With its CAP®GT cell lines, CEVEC provides a novel platform for the industrial scale production of viral vectors for gene therapy applications. Growing in serum-free suspension culture, CA®GT provides outstanding production capabilities and high cell densities allowing for easier scale-up and reduced production costs when compared to adherent cell culture systems including HEK293.
Financial terms: Financial details of this agreement were not disclosed.
Latest news:
